MX2021004474A - Compuestos que contienen deuterio. - Google Patents

Compuestos que contienen deuterio.

Info

Publication number
MX2021004474A
MX2021004474A MX2021004474A MX2021004474A MX2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A
Authority
MX
Mexico
Prior art keywords
deuterium
compounds containing
containing deuterium
compounds
formula
Prior art date
Application number
MX2021004474A
Other languages
English (en)
Inventor
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of MX2021004474A publication Critical patent/MX2021004474A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un compuesto de fórmula (I), o una sal farmacéuticamente aceptable de este (Fórmula I), (ver Fórmula) en donde, cada R1-R30 se selecciona independientemente del grupo que consiste en H y deuterio, y al menos uno de R1-R30 es deuterio con un nivel de abundancia mayor que la abundancia natural de deuterio; la invención también proporciona composiciones farmacéuticas que contienen los compuestos, y usos de los compuestos.
MX2021004474A 2018-10-18 2019-10-17 Compuestos que contienen deuterio. MX2021004474A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Publications (1)

Publication Number Publication Date
MX2021004474A true MX2021004474A (es) 2021-08-24

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004474A MX2021004474A (es) 2018-10-18 2019-10-17 Compuestos que contienen deuterio.

Country Status (19)

Country Link
US (1) US20210388024A1 (es)
EP (1) EP3866931B1 (es)
JP (1) JP2022512736A (es)
KR (1) KR20210078487A (es)
CN (1) CN112930214A (es)
AU (1) AU2019362389A1 (es)
BR (1) BR112021007060A2 (es)
CA (1) CA3116198A1 (es)
DK (1) DK3866931T3 (es)
ES (1) ES2942468T3 (es)
FI (1) FI3866931T3 (es)
HU (1) HUE061801T2 (es)
IL (1) IL282231A (es)
MA (1) MA53904A (es)
MX (1) MX2021004474A (es)
PL (1) PL3866931T3 (es)
SG (1) SG11202103726RA (es)
WO (1) WO2020079165A1 (es)
ZA (1) ZA202102492B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615A1 (en) * 2021-06-01 2024-04-10 Synthon B.V. Process for making melflufen or a salt thereof
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) * 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
PT3656393T (pt) * 2011-04-28 2022-11-03 Oncopeptides Ab Preparação liofilizada de dipéptidos citotóxicos
CA2889753C (en) * 2012-10-26 2021-03-02 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
KR20150115807A (ko) * 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Also Published As

Publication number Publication date
HUE061801T2 (hu) 2023-08-28
DK3866931T3 (da) 2023-04-24
SG11202103726RA (en) 2021-05-28
AU2019362389A1 (en) 2021-06-03
FI3866931T3 (fi) 2023-05-10
CN112930214A (zh) 2021-06-08
US20210388024A1 (en) 2021-12-16
PL3866931T3 (pl) 2023-06-19
WO2020079165A1 (en) 2020-04-23
JP2022512736A (ja) 2022-02-07
EP3866931A1 (en) 2021-08-25
ES2942468T3 (es) 2023-06-01
KR20210078487A (ko) 2021-06-28
EP3866931B1 (en) 2023-02-15
BR112021007060A2 (pt) 2021-07-20
CA3116198A1 (en) 2020-04-23
ZA202102492B (en) 2024-04-24
MA53904A (fr) 2021-08-25
IL282231A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
MX2021004474A (es) Compuestos que contienen deuterio.
WO2017019804A3 (en) Compounds and methods for kinase modulation, and indications therefor
CR20210247A (es) Nuevos compuestos heterocíclicos
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
CR20210032A (es) Compuestos
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
SG11201810704WA (en) Sulfonamide compound or salt thereof
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
CR20200382A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
MX2018001925A (es) Composiciones que comprenden compuestos triciclicos heterociclicos.
WO2018039077A8 (en) Therapeutic compounds
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2021014680A (es) Derivado de benzotriazol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
CR20220004A (es) Nuevos compuestos heterocíclicos
MX2022000939A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
WO2018102256A8 (en) Pyrrolidinone compounds
MX2021014458A (es) Compuestos triciclicos.
PH12020550549A1 (en) Compositions for preventing or treating lupus
AU2019328154A8 (en) Pyrazole compounds, pharmaceutical compositions thereof and use thereof